Table 2.

Primary and secondary outcomes for patients with SLE/APS in both cohorts

Pregnancies (n)	SLE (±secondary APS)		Primary APS (thrombotic+obstetric)
	Pathway N=16	Historical N=43	Pathway N=25	Historical N=28
Disease outcomes
SLE flare	2 (12.5)	17 (39.5)	–	–
Major SLE flare	1 (6.3)	7 (16.3)	–	–
Kidney	0/1 (0.0)	6/7 (85.7)	–	–
Heart/Lungs	1/1 (100.0)	0/7 (0.0)	–	–
Nervous system	0/1 (0.0)	0/7 (0.0)	–	–
Haematological	0/1 (0.0)	2/7 (28.6)	–	–
Minor SLE flare	1 (6.3)	10 (23.3)	–	–
Joints	1/1 (100.0)	8/10 (80.0)	–	–
Skin	0/1 (0.0)	4/10 (40.0)	–	–
SLEPDAI*	7 (6–8)	4 (2–16)	–	–
Thromboembolic events	0 (0.0)	0 (0.0)	1 (4.0)	3 (10.7)
Maternal outcomes
Miscarriage	0 (0.0)	3 (7.0)	10 (40.0)	14 (50.0)
<10 weeks	0 (0.0)	3 (7.0)	10 (40.0)	9 (32.1)
10–16 weeks	0 (0.0)	0 (0.0)	0 (0.0)	5 (17.9)
Gestational hypertension†	1 (6.3)	2 (5.0)	2 (13.3)	0 (0.0)
Severe hypertensive disease†	5 (31.3)	13 (32.5)	4 (26.7)	4 (28.6)
Vaginal delivery†	11 (68.8)	25 (62.5)	7 (46.7)	9 (64.3)
Fetal outcomes
Perinatal death†	1 (6.3)	1 (2.5)	0 (0.0)	0 (0.0)
FGR (EFW <p10)†	3 (18.8)	8 (20.0)	1 (6.7)	1 (7.1)
Preterm birth <37 weeks†	6 (37.5)	15 (37.5)	6 (40.0)	3 (21.4)
Preterm birth <32 weeks†	1 (6.3)	5 (12.5)	1 (6.7)	2 (14.3)
Congenital heart block†	0 (0.0)	1 (2.5)	0 (0.0)	0 (0.0)
NICU admission†	2 (12.5)	7 (17.5)	1 (6.7)	2 (14.3)

Data depicted as number of pregnancies (% of cohort).

Severe hypertensive disease=pre-eclampsia, eclampsia or HELLP.

*Median (minimum, maximum).

†For calculations miscarriages were excluded.

APS, antiphospholipid syndrome; EFW, estimated fetal weight; FGR, fetal growth restriction; HELLP, haemolysis elevated liver enzymes low platelets; NICU, neonatal intensive care unit; SLEPDAI, Systemic Lupus Erythematosus Pregnancy Disease Activity Index.